<DOC>
	<DOCNO>NCT02533505</DOCNO>
	<brief_summary>A Phase IV study evaluate change oxygen consumption cardiac function Subjects Chronic obstructive pulmonary disease ( COPD ) rest hyperinflation administration Symbicort pMDI 160/4.5 μg .</brief_summary>
	<brief_title>Phase IV O2 Consumption Study COPD Patients</brief_title>
	<detailed_description>Patients moderate/severe COPD know static hyperinflation develop dynamic hyperinflation exercise . Treatment inhale long-acting beta agonist combination long-acting beta agonist ( LABA ) , formoterol inhale corticosteroid , budesonide show improve IC decrease lung hyperinflation . In similar previous pilot single centre study budesonide/formoterol ( Symbicort® ) analysis cardiac outcomes demonstrated decrease maximum volume oxygen ( VO2 ) compare placebo . Findings suggest use Symbicort decrease cost breathe therefore reduce cardiac demand experience COPD patient hyperinflation rest . The aim study investigate whether Symbicort therapy decrease rest VO2 decrease static lung hyperinflation subject COPD evaluate change cardiac function .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Signing informed consent form ( ICF ) prior study specific procedure , include withhold medication . 2 . Male female , age 40 80 year , inclusive , Screening ( Visit 1 ) . 3 . Has clinical diagnosis COPD accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) 2014 guideline post bronchodilator FEV1/FVC &lt; 0.7 Screening ( Visit 1 ) . 4 . Has postbronchodilator FEV1 ≤65 % predict value Screening ( Visit 1 ) . National Health Nutrition Examination Survey ( NHANES ) predict normal standard use subject . 5 . Has increase IC &gt; 10 % administration 1 inhalation openlabel Symbicort pMDI administer spacer Screening ( Visit 1 ) . 6 . Has cigarette smoke history 10 packyears ( number cigarette smoke per day × number year smoke ) /20 ) . 7 . Be able understand comply study requirement , judge Investigator . 1 . Subject employee relative employee involve planning and/or conduct study ( applies AstraZeneca staff and/or staff study site ) . 2 . Previous enrollment randomization study . 3 . Participation another clinical study investigational product ( IP ) last 30 day prior Screening ( Visit 1 ) . 4 . Subjects unable discontinue regular chronic COPD medication ( include LAMAs and/or LABA/ICS ) and/or unable unwilling comply study requirement . 5 . Subjects take uLABAs ( indacaterol , vilanterol ) uLABAcontaining product . 6 . Subjects take PDE4 inhibitor ( roflumilast ) . 7 . Subjects take oral corticosteroid chronic , regular basis . 8 . Subjects use daytime oxygen therapy . 9 . Subjects currently pregnant ( confirm positive pregnancy test ) breast feeding . 10 . History respiratory tract infection ( include upper respiratory tract ) and/or pulmonary exacerbation within 6 week prior Screening ( Visit 1 ) . 11 . Pulmonary resection lung volume reduction surgery within 12 month prior Screening ( Visit 1 ) , history lung transplantation , , Investigator 's opinion , subject may need thoracotomy lung surgery study . 12 . History current diagnosis asthma and/or alpha 1 antitrypsin deficiency . 13 . Known active tuberculosis . 14 . History interstitial lung massive pulmonary thromboembolic disease . 15 . History bronchiectasis secondary respiratory disease COPD ( eg , cystic fibrosis , Kartagener 's syndrome , etc ) . 16 . Any clinically significant disease disorder ( eg , cardiovascular , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , psychiatric , major physical impairment ) , opinion Investigator , may put subject risk participation study , may influence result study , may affect subject 's ability participate study . 17 . Recent ( within 12 month prior Screening [ Visit 1 ] ) history myocardial infarction , recent history heart failure ( New York Heart Association [ NYHA ] class III IV , pulmonary edema , and/or cardiac arrhythmia . 18 . Previous current history lung cancer . 19 . History cancer ( within 5 year prior Visit 1 ) , except nonmetastatic , non melanoma skin cancer . 20 . Subjects perform spirometry manuevers tolerate body plethysmography . 21 . Subjects know hypersensitivity Symbicort , monocomponents ( budesonide formoterol ) , excipients .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Respiratory</keyword>
	<keyword>COPD</keyword>
	<keyword>O2 Consumption</keyword>
</DOC>